Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

Leukemia

Volumn 16, Issue 10, 2002, Pages 2092-2095

  Gupta, N ^a   Kavuru, S ^a   Patel, D ^a   Janson, D ^a   Driscoll, N ^a   Ahmed, S ^a   Raid, K R ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Autoimmune hemolytic anemia; Chronic lymphocytic leukemia; Rituximab

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HEMOGLOBIN; PARACETAMOL; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COOMBS TEST; DRUG EFFICACY; FEMALE; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTENSION; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RASH; REMISSION; RETREATMENT; TREATMENT OUTCOME;

EID: 0036796786     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402676     Document Type: Article

References (22)

1. Hamblin TJ, Oscier DJ, Young BJ. Autoimmuntiy in chronic lymphocytic leukemia. J Clin Pathol 1986; 39: 713-719.
2. Mauro F, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia. Clinical, therapeutic and prognostic features. Blood 2000; 95: 2786-2792.
3. Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med 1987; 82: 159-162.
4. Emilia G, Messora C, Bensi L. The use of cyclosporine-A in the treatment of B-chronic lymphocytic leukemia. Leukemia 1995; 9: 357-359.
5. Caligaris-Cappio F, Hamblin T. B-cell chronic lymphocytic leukemia. A bird of a different feather. J Clin Oncol 1999; 17: 399-408.
6. Nadler LM, Ritz J, Hardy R, Van Agthoren A, Terhorst C, Schlossman S. A unique cell surface antigen identifying lymphoid malignancies of B-cell origin. J Clin Invest 1981; 167: 134-140.
7. Anderson KS, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman S, Nadler LM. Expression of human B-cell associated antigen on leukemia and lymphomas: a model of human B-cell differentiation. Blood 1994; 63: 1424-1433.
8. Reff ME, Carmer K, Chambers KS, Chinn P, Leonard J, Raab R, Newman R, Anderson D. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD-20. Blood 1994; 83: 435-445.
9. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman M, Heyman M, White C, Jain V, Ho A, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 antibody therapy for relapsed indolent lymphoma: half of the patients responded to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
10. Huhn D, Schiling C, Wilhelm M, Ho A, Hallek M, Knauf W, Riedel U, Srock S, Serke S, Emmerich B, for the German CLL Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98: 1326-1331.
11. Byrd J, Peterson B, Park K, Morrison V, Vardiman J, Jacobson R, Rai KR, Larson R. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712. Proc Am Acad Oncol 2001; 20: 280a.
12. Saleh MN, Gutheil J, Moore M. A pilot study of anti-CD MoAb Rituximab in patients with refractory immune thrombocytopenic purpura (ITP). Blood 2000; 95: 252a.
13. Mow BM, Hook CC. Rituximab for the treatment of refractory immune thrombocytopenia: a case report. Blood 1999; 94 (Suppl. 1): 82b.
14. Perrotta AL, Sunneberg TA, Scott J. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood 1999; 94: 14a.
15. Lee E, Zamkoff K, Gentile T. Rituxan in the treatment of autoimmune hemolytic anemia (AIHA). Blood 2000; 95: 596a.
16. Berentsen S, Tjonnfjord G, Gjertsen B. Rituxan therapy for chronic cold agglutinin disease. Blood 2000; 95: 730a.
17. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti CD20 monoclonal antibody treatment for adults with idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
18. Treon S, Anderson K. The use of rituximab in the treatment of malignant and non malignant plasma cell disorders. Semin Oncol 2000; 27: 79-85.
19. Demidem A, Lam T, Alas S, Hariharan K, Hanna A, Bonavida B. chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
20. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
21. Di Raimondo F, Giustolisi R, Cacciola E, O' Brien S, Kantarjian H, Robertson L, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11: 63-68.
22. Weiss R, Freiman J, Kweder S, Diehl L, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 1885-1889.